TY - JOUR
T1 - Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP)
T2 - Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents
AU - Williams, Michelle D.
AU - Liu, Zhiyan
AU - Rossi, Esther Diana
AU - Agarwal, Shipra
AU - Ryška, Aleš
AU - Ghuzlan, Abir Al
AU - Bychkov, Andrey
AU - Baloch, Zubair
AU - Chernock, Rebecca
AU - Chiosea, Simion L.
AU - Cipriani, Nicole A.
AU - Erkilic, Suna
AU - Fridman, Michael
AU - Hang, Jen Fan
AU - Harahap, Agnes Stephanie
AU - Jung, Chan Kwon
AU - Kakudo, Kennichi
AU - Khalil, Moosa
AU - Khanafshar, Elham
AU - Kumarasinghe, Priyanthi
AU - Lloyd, Ricardo
AU - Nguyen, Truong Phan Xuan
AU - Ocal, Idris Tolgay
AU - Prasad, Manju L.
AU - Pusztaszeri, Marc
AU - Rana, Chanchal
AU - Sadow, Peter
AU - Sajed, Dipti P.
AU - Seethala, Raja
AU - Tallini, Giovanni
AU - Vuong, Huy Gia
AU - Yegen, Gülçin
AU - LiVolsi, Virginia A.
AU - Nikiforov, Yuri E.
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.per
PY - 2024/12/18
Y1 - 2024/12/18
N2 - CONTEXT: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced as a new entity replacing the diagnosis of noninvasive encapsulated follicular variant of papillary thyroid carcinoma (PTC). Significant variability in the incidence of NIFTP diagnosed in different world regions has been reported. OBJECTIVE: To investigate the rate of adoption of NIFTP, change in practice patterns, and uniformity in applying diagnostic criteria among pathologists practicing in different regions. METHODS: Two surveys distributed to pathologists of the International Endocrine Pathology Discussion Group with multiple-choice questions on NIFTP adoption into pathology practice and whole slide images of 5 tumors to collect information on nuclear score and diagnosis. Forty-eight endocrine pathologists, including 24 from North America, 8 from Europe, and 16 from Asia/Oceania completed the first survey and 38 the second survey. RESULTS: A 94% adoption rate of NIFTP by the pathologists was found. Yet, the frequency of rendering NIFTP diagnosis was significantly higher in North America than in other regions (P = .009). While the highest concordance was found in diagnosing lesions with mildly or well-developed PTC-like nuclei, there was significant variability in nuclear scoring and diagnosing NIFTP for tumors with moderate nuclear changes (nuclear score 2) (case 2, P < .05). Pathologists practicing in North America and Europe showed a tendency for lower thresholds for PTC-like nuclei and NIFTP than those practicing in Asia/Oceania. CONCLUSION: Despite a high adoption rate of NIFTP across geographic regions, NIFTP is diagnosed more often by pathologists in North America. Significant differences remain in diagnosing intermediate PTC-like nuclei and respectively NIFTP, with more conservative nuclear scoring in Asia/Oceania, which may explain the geographic differences in NIFTP incidence.
AB - CONTEXT: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced as a new entity replacing the diagnosis of noninvasive encapsulated follicular variant of papillary thyroid carcinoma (PTC). Significant variability in the incidence of NIFTP diagnosed in different world regions has been reported. OBJECTIVE: To investigate the rate of adoption of NIFTP, change in practice patterns, and uniformity in applying diagnostic criteria among pathologists practicing in different regions. METHODS: Two surveys distributed to pathologists of the International Endocrine Pathology Discussion Group with multiple-choice questions on NIFTP adoption into pathology practice and whole slide images of 5 tumors to collect information on nuclear score and diagnosis. Forty-eight endocrine pathologists, including 24 from North America, 8 from Europe, and 16 from Asia/Oceania completed the first survey and 38 the second survey. RESULTS: A 94% adoption rate of NIFTP by the pathologists was found. Yet, the frequency of rendering NIFTP diagnosis was significantly higher in North America than in other regions (P = .009). While the highest concordance was found in diagnosing lesions with mildly or well-developed PTC-like nuclei, there was significant variability in nuclear scoring and diagnosing NIFTP for tumors with moderate nuclear changes (nuclear score 2) (case 2, P < .05). Pathologists practicing in North America and Europe showed a tendency for lower thresholds for PTC-like nuclei and NIFTP than those practicing in Asia/Oceania. CONCLUSION: Despite a high adoption rate of NIFTP across geographic regions, NIFTP is diagnosed more often by pathologists in North America. Significant differences remain in diagnosing intermediate PTC-like nuclei and respectively NIFTP, with more conservative nuclear scoring in Asia/Oceania, which may explain the geographic differences in NIFTP incidence.
KW - NIFTP
KW - nuclear score
KW - papillary carcinoma
KW - pathology
KW - thyroid tumors
UR - http://www.scopus.com/inward/record.url?scp=85209253571&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgae354
DO - 10.1210/clinem/dgae354
M3 - Article
C2 - 38874075
AN - SCOPUS:85209253571
SN - 0021-972X
VL - 110
SP - 166
EP - 175
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 1
ER -